Publications – Melanoma Research Victoria https://melanomaresearchvic.com.au Thu, 21 Jan 2021 04:53:54 +0000 en-US hourly 1 https://melanomaresearchvic.com.au/wp-content/uploads/2017/12/cropped-favicon-32x32.png Publications – Melanoma Research Victoria https://melanomaresearchvic.com.au 32 32 The State of Melanoma: Emergent Challenges and Opportunities https://melanomaresearchvic.com.au/the-state-of-melanoma-emergent-challenges-and-opportunities Mon, 25 Jan 2021 04:51:42 +0000 https://melanomaresearchvic.com.au/?p=16259 Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma.

The post The State of Melanoma: Emergent Challenges and Opportunities appeared first on Melanoma Research Victoria.

]]>
Source: docwirenews, January 2021

Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma.

Since then, remarkable progress has been made on both the basic and clinical research fronts.

However, the incidence, recurrence and death rates for melanoma remain unacceptably high and significant challenges remain.

READ THE ORIGINAL FULL ARTICLE

The post The State of Melanoma: Emergent Challenges and Opportunities appeared first on Melanoma Research Victoria.

]]>
FDA Grants Orphan Drug Designation to Novel Immunotherapy in Advanced Melanoma https://melanomaresearchvic.com.au/fda-grants-orphan-drug-designation-to-novel-immunotherapy-in-advanced-melanoma Mon, 25 Jan 2021 04:48:28 +0000 https://melanomaresearchvic.com.au/?p=16257 The FDA has granted an Orphan Drug designation to the novel immunotherapy PVSRIPO for the treatment of patients with advanced melanoma of stage IIB-IV, Istari Oncology, Inc., announced in a press release.1

The post FDA Grants Orphan Drug Designation to Novel Immunotherapy in Advanced Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: Targeted Oncology, January 2021

The FDA has granted an Orphan Drug designation to the novel immunotherapy PVSRIPO for the treatment of patients with advanced melanoma of stage IIB-IV, Istari Oncology, Inc., announced in a press release.1

The agent is under evaluation currently in a phase 2 study known as LUMINOS-102 (NCT04577807), which follows a successful phase 1 study of PVSRIPO as monotherapy in patients with anti-PD-1 refractory advanced melanoma.

“We are encouraged by the data from our phase 1 trial presented at last year’s Society for Immunotherapy of Cancer (SITC) 2020 annual meeting,” said Garrett Nichols, MD, MS, chief medical officer, Istari Oncology, in a statement.

READ THE ORIGINAL FULL ARTICLE

The post FDA Grants Orphan Drug Designation to Novel Immunotherapy in Advanced Melanoma appeared first on Melanoma Research Victoria.

]]>
Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: An open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402) https://melanomaresearchvic.com.au/nivolumab-plus-ipilimumab-for-treatment-naive-metastatic-uveal-melanoma-an-open-label-multicenter-phase-ii-trial-by-the-spanish-multidisciplinary-melanoma-group-gem-1402 Thu, 21 Jan 2021 06:41:29 +0000 https://melanomaresearchvic.com.au/?p=16249 In this single-arm, phase II trial, researchers sought to evaluate the effectiveness of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligible for liver resection.

The post Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: An open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402) appeared first on Melanoma Research Victoria.

]]>
Source: MDLinx, January 2021

In this single-arm, phase II trial, researchers sought to evaluate the effectiveness of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligible for liver resection.

In total, 52 patients with a median age of 59 years (range, 26-84 years) were registered.

During four inductions, nivo (1 mg/kg once every 3 weeks) and ipi (3 mg/kg once every 3 weeks) were given, followed by nivo (3 mg/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal.

READ THE ORIGINAL FULL ARTICLE

The post Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: An open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402) appeared first on Melanoma Research Victoria.

]]>
Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival https://melanomaresearchvic.com.au/incidence-of-thromboembolism-in-patients-with-melanoma-on-immune-checkpoint-inhibitor-therapy-and-its-adverse-association-with-survival Wed, 20 Jan 2021 06:29:17 +0000 https://melanomaresearchvic.com.au/?p=16243 Thromboembolism (TE) in cancer significantly contributes to morbidity and mortality. Little is known about the incidence of arterial TE (ATE) and venous TE (VTE) in patients with melanoma on immune checkpoint inhibitor (ICI) therapy.

The post Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival appeared first on Melanoma Research Victoria.

]]>
Source: docwirenews, January 2021

Thromboembolism (TE) in cancer significantly contributes to morbidity and mortality. Little is known about the incidence of arterial TE (ATE) and venous TE (VTE) in patients with melanoma on immune checkpoint inhibitor (ICI) therapy.

We conducted a retrospective cohort study of patients with melanoma receiving ICI from July 2015 through December 2017 at the Cleveland Clinic.

TE, including VTE events of deep venous thrombosis, pulmonary embolism, visceral vein thrombosis, and ATE events of myocardial infarction, stroke, peripheral arterial embolism, or transient ischemic attack after ICI initiation were identified.

READ THE ORIGINAL FULL ARTICLE

The post Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival appeared first on Melanoma Research Victoria.

]]>
The Yin and Yang of BRAF, MEK and CDK4-6 targeted therapy https://melanomaresearchvic.com.au/the-yin-and-yang-of-braf-mek-and-cdk4-6-targeted-therapy Mon, 18 Jan 2021 04:49:44 +0000 https://melanomaresearchvic.com.au/?p=16222 A new paper from the McArthur & Sheppard Laboratory, by Emily Lelliott et. al.

The post The Yin and Yang of BRAF, MEK and CDK4-6 targeted therapy appeared first on Melanoma Research Victoria.

]]>
A new paper from the McArthur & Sheppard Laboratory, by Emily Lelliott et. al.

Download PDF File

The post The Yin and Yang of BRAF, MEK and CDK4-6 targeted therapy appeared first on Melanoma Research Victoria.

]]>
Damage-associated molecular pattern (DAMP) activation in melanoma: investigation of the immunogenic activity of 15-deoxy, Δ12,14 prostamide J2 https://melanomaresearchvic.com.au/damage-associated-molecular-pattern-damp-activation-in-melanoma-investigation-of-the-immunogenic-activity-of-15-deoxy-1214-prostamide-j2 Mon, 18 Jan 2021 04:43:09 +0000 https://melanomaresearchvic.com.au/?p=16218 Metastatic melanoma is the most deadly skin neoplasm in the United States.

The post Damage-associated molecular pattern (DAMP) activation in melanoma: investigation of the immunogenic activity of 15-deoxy, Δ12,14 prostamide J2 appeared first on Melanoma Research Victoria.

]]>
Source: docwirenews, January 2021

Metastatic melanoma is the most deadly skin neoplasm in the United States.

Outcomes for this lethal disease have improved dramatically due to the use of both targeted and immunostimulatory drugs.

Immunogenic cell death (ICD) has emerged as another approach for initiating antitumor immunity.

READ THE ORIGINAL FULL ARTICLE

The post Damage-associated molecular pattern (DAMP) activation in melanoma: investigation of the immunogenic activity of 15-deoxy, Δ12,14 prostamide J2 appeared first on Melanoma Research Victoria.

]]>
Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis https://melanomaresearchvic.com.au/immune-checkpoint-inhibitor-therapy-may-increase-the-incidence-of-treatment-related-necrosis-after-stereotactic-radiosurgery-for-brain-metastases-a-systematic-review-and-meta-analysis Fri, 15 Jan 2021 12:52:17 +0000 https://melanomaresearchvic.com.au/?p=16212 OBJECTIVES: To compare the incidence of treatment-related necrosis between combination SRS+ICI therapy and SRS therapy alone in patients with brain metastases from melanoma and non-small cell lung cancer (NSCLC).

The post Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis appeared first on Melanoma Research Victoria.

]]>
Source: docwirenews, November 2020

OBJECTIVES: To compare the incidence of treatment-related necrosis between combination SRS+ICI therapy and SRS therapy alone in patients with brain metastases from melanoma and non-small cell lung cancer (NSCLC).

METHODS: A systematic literature search of Ovid-MEDLINE and EMBASE was performed up to August 10, 2020.

The difference in the pooled incidence of treatment-related necrosis after SRS+ICI or SRS alone was evaluated.

READ THE ORIGINAL FULL ARTICLE

The post Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis appeared first on Melanoma Research Victoria.

]]>
Comparison of mortality and medical complications between older and younger malignant melanoma inpatients https://melanomaresearchvic.com.au/comparison-of-mortality-and-medical-complications-between-older-and-younger-malignant-melanoma-inpatients-2 Thu, 14 Jan 2021 12:22:15 +0000 https://melanomaresearchvic.com.au/?p=16199 Because older age has been reported as a negative prognostic factor in malignant melanoma patients in the previous studies, therefore, researchers compared younger and older malignant melanoma inpatients, in terms of comorbidities, medical complications, and inpatient mortality.

The post Comparison of mortality and medical complications between older and younger malignant melanoma inpatients appeared first on Melanoma Research Victoria.

]]>
Source: MDLinx, December 2020

Because older age has been reported as a negative prognostic factor in malignant melanoma patients in the previous studies, therefore, researchers compared younger and older malignant melanoma inpatients, in terms of comorbidities, medical complications, and inpatient mortality.

For this purpose, they used the 2003 to 2012 National Inpatient Sample database.

In multivariable analysis of medical complications, there was a greater chance of encountering urinary tract infection but less likelihood of having acute respiratory failure and venous thromboembolism in older adult inpatients.

READ THE ORIGINAL FULL ARTICLE

The post Comparison of mortality and medical complications between older and younger malignant melanoma inpatients appeared first on Melanoma Research Victoria.

]]>
Clinical utility of skin cancer and melanoma risk scores for population screening: TRoPICS study https://melanomaresearchvic.com.au/clinical-utility-of-skin-cancer-and-melanoma-risk-scores-for-population-screening-tropics-study Wed, 06 Jan 2021 05:40:33 +0000 https://melanomaresearchvic.com.au/?p=16164 Researchers conducted the study for evaluating the clinical utility of risk?assessment tools to identify people with prevalent skin cancers in a volunteer?based screening clinic.

The post Clinical utility of skin cancer and melanoma risk scores for population screening: TRoPICS study appeared first on Melanoma Research Victoria.

]]>
Source: MDLinx, December 2020

Researchers conducted the study for evaluating the clinical utility of risk-assessment tools to identify people with prevalent skin cancers in a volunteer-based screening clinic.

Participants in the study were adults presenting at a volunteer-based skin cancer screening facility for a skin check.

Five hundred seven (64%) of 789 individuals who presented to the clinic consented to the study.

READ THE ORIGINAL FULL ARTICLE

The post Clinical utility of skin cancer and melanoma risk scores for population screening: TRoPICS study appeared first on Melanoma Research Victoria.

]]>
Indoor tanning exposure in association with multiple primary melanoma https://melanomaresearchvic.com.au/indoor-tanning-exposure-in-association-with-multiple-primary-melanoma Tue, 29 Dec 2020 04:34:23 +0000 https://melanomaresearchvic.com.au/?p=16123 Researchers undertook this retrospective case?control study to examine the link between indoor tanning and the development of multiple primary melanoma.

The post Indoor tanning exposure in association with multiple primary melanoma appeared first on Melanoma Research Victoria.

]]>
Source: MDLinx, November 2020

Researchers undertook this retrospective case-control study to examine the link between indoor tanning and the development of multiple primary melanoma.

To assess the link between multiple primary melanoma and risk factors, experts employed logistic regression models.

This study involved 330 patients (39.1% men) with a median age of 51 years.

READ THE ORIGINAL FULL ARTICLE

 

The post Indoor tanning exposure in association with multiple primary melanoma appeared first on Melanoma Research Victoria.

]]>